Trial Profile
A Phase 1, Open-Label, Multiple-Dose, Drug-Drug Interaction Study (DDI) Evaluating Pharmacokinetics, Tolerability And Safety Of Glecaprevir Plus Pibrentasvir Co-administered With ELV/COBI/FTC/TAF (Genvoya) or DTG/ABC/3TC (Triumeq)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2017
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Glecaprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 24 Mar 2017 New trial record
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections.